[시장보고서]세계의 면역측정 분석기 시장 규모, 점유율, 동향 분석 보고서 : 제품별, 용도별, 최종 용도별, 지역별, 부문 예측(2025-2030년)

세계의 면역측정 분석기 시장 규모, 점유율, 동향 분석 보고서 : 제품별, 용도별, 최종 용도별, 지역별, 부문 예측(2025-2030년)

Immunoassay Analyzers Market Size, Share & Trends Analysis Report By Product (Chemiluminescence Immunoassays, Fluorescence Immunoassay, Radioimmunoassay), By Application (Oncology, Cardiology), By End-use, By Region And Segment Forecasts, 2025 - 2030

상품코드 : 1701259

리서치사 : Grand View Research

발행일 : 2025년 03월

페이지 정보 : 영문 150 Pages

라이선스 & 가격 (부가세 별도)

US $ 5,950

￦ 8,590,000

Unprintable PDF & Excel (Single User License)

보고서 PDF 및 엑셀을 1인만 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 불가능합니다.

US $ 6,950

￦ 10,034,000

Printable PDF & Excel (5-User License)

보고서 PDF 및 엑셀을 동일 기업 내 동일 부서에서 최대 5명까지 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다.

US $ 8,950

￦ 12,922,000

Printable PDF & Excel (Enterprise License)

PDF & Excel 보고서를 동일 기업(자회사 포함)의 모든 분이 이용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다. 인쇄물의 이용 범위는 파일의 이용 범위와 동일합니다.

ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.

한글목차

샘플 요청 목록에 추가

면역 측정 분석기 시장 동향 :

면역 측정 분석기 세계 시장 규모는 2024년 71억 8,000만 달러로 추정되며, 2025년부터 2030년까지 연평균 4.13% 성장할 것으로 예측됩니다.

감염성 및 비감염성 질환을 포함한 만성 질환 증가는 면역 측정 분석기 시장 성장의 중요한 촉진제입니다. 암, 심혈관 질환과 같은 질병의 부담이 증가함에 따라 기술 발전과 면역 분석 장비의 적용이 빠르게 확대되고 있습니다. 이러한 발전은 조기 진단, 질병 모니터링 및 치료 계획에서 중요한 역할을 하고 있습니다. 세계보건기구(WHO)는 2022년에 약 2,000만 명이 새롭게 암에 걸릴 것으로 보고하고 있으며, 향후 몇 년 동안 진단 건수는 5,350만 건에 달할 것으로 예측했습니다. 이러한 만성 질환의 급증은 혁신적인 면역 분석 솔루션에 대한 수요를 촉진하고 있으며, 주요 기업들은 보다 진보되고 효과적인 진단 기술을 개발하기 위해 노력하고 있습니다.

코로나19 팬데믹은 신속하고 정확한 진단 도구의 필요성을 더욱 강조했으며, SARS-CoV-2 바이러스의 출현으로 정확성과 경제성을 모두 갖춘 가속 진단 방법에 대한 긴급한 수요가 발생했습니다. 하지만, 고가의 자원을 필요로 하는 경우가 많아졌습니다. 이에 따라 항체를 검출하는 면역 분석기가 널리 도입되어 보다 비용 효율적이고 효율적인 대안을 제공하게 되었습니다. 각 업체들은 이러한 수요에 발 빠르게 대응하여 첨단 면역 분석 솔루션을 출시했습니다. 예를 들어, Agilent Technologies, Inc.는 인간 혈청 또는 혈장에서 SARS-CoV-2 항체를 검출하도록 설계된 Agilent Dako SARS-CoV-2 효소 결합 면역 분석 키트를 발표했습니다. 팬데믹은 면역 분석기기의 기능에 대한 인식을 높이고 기술 개발 및 시장 개척을 가속화했습니다.

만성 질환 증가는 면역 측정 기술의 지속적인 발전을 촉진했습니다. 새로운 감염성 질환의 출현, 항생제 내성에 대한 우려 증가, 개인 맞춤형 의료에 대한 수요 증가로 인해 고감도, 특이적, 신속한 면역 분석 검사의 필요성이 더욱 커지고 있습니다. 다양한 기업들이 이러한 진화하는 헬스케어 요구에 대응하기 위해 혁신적인 솔루션에 투자하고 있습니다. 예를 들어, 다이아몬드 진단(Diamond Diagnostics)은 면역측정 분석기기를 위한 고품질의 비용 효율적인 소모품 및 액세서리를 생산하여 면역측정 진단을 강화하기 위해 노력하고 있습니다. 이러한 기술 혁신은 의료진이 신뢰할 수 있는 고급 진단 도구를 사용할 수 있게 함으로써 시장 확대에 기여하고 있습니다.

기술 발전과 더불어 주요 기업 간의 전략적 제휴도 시장 성장에 크게 기여하고 있습니다. 각 기업들은 면역 분석 역량 강화, 치료법 발전 지원, 임상 채택 촉진 등을 위해 제휴를 맺는 사례가 늘고 있습니다. 주목할 만한 사례로 2023년 7월 Beckman Coulter, Inc.와 Fujirebio의 제휴를 들 수 있습니다. 이 제휴는 신경 퇴행성 질환 연구, 임상시험, 일상적인 진단 및 상환 과정에서 면역 측정 용도를 강화하는 것을 목표로 하고 있습니다. 전문 지식과 자원을 결합하여 혁신을 촉진하고 고급 진단 솔루션의 접근성을 향상시키기 위해 제휴를 맺었습니다.

지역별 시장 점유율 분석, 2024년 및 2030년
지역 시장 대시보드
세계 지역 시장 스냅숏
시장 규모, 예측 동향 분석, 2018-2030년까지 :
북미
- 북미 : SWOT 분석
- 미국
- 캐나다
- 멕시코
유럽
- 유럽 : SWOT 분석
- 영국
- 독일
- 프랑스
- 이탈리아
- 스페인
- 노르웨이
- 스웨덴
- 덴마크
아시아태평양
- 아시아태평양 : SWOT 분석
- 일본
- 중국
- 인도
- 호주
- 한국
- 태국
라틴아메리카
- 라틴아메리카 : SWOT 분석
- 브라질
- 아르헨티나
중동 및 아프리카
- 중동 및 아프리카(MEA) : SWOT 분석
- 남아프리카공화국
- 사우디아라비아
- 아랍에미리트(UAE)
- 쿠웨이트

제8장 경쟁 구도

주요 시장 진출기업의 최근 동향과 영향 분석
기업/경쟁 분류
벤더 구도
- 주요 유통업체 및 채널 파트너 리스트
- 주요 고객
- 주요 기업의 시장 점유율 분석(2024년)
- Siemens Healthineers AG
- BIOMERIEUX
- FAbbott
- QuidelOrtho Corporation
- Sysmex Corporation
- BD
- Thermo Fisher Scientific Inc.
- F. Hoffmann-La Roche Ltd
- Beckman Coulter, Inc.
- DiaSorin SpA

LSH

영문 목차

영문목차

Immunoassay Analyzers Market Trends:

The global Immunoassay analyzers market size was estimated at USD 7.18 billion in 2024 and is expected to grow at a CAGR of 4.13% from 2025 to 2030. The increasing prevalence of chronic diseases, including both infectious and non-infectious conditions, is a significant driver of market growth for immunoassay analyzers. As the burden of diseases such as cancer and cardiovascular conditions continues to rise, technological advancements and the application of immunoassay analyzers are expanding rapidly. These advancements play a crucial role in early diagnosis, disease monitoring, and treatment planning. The World Health Organization (WHO) reported approximately 20 million new cancer cases in 2022, with a projected increase in diagnoses reaching 53.5 million in the coming years. This surge in chronic illnesses is fueling the demand for innovative immunoassay solutions, leading companies to develop more advanced and effective diagnostic technologies.

The outbreak of the COVID-19 pandemic further emphasized the need for rapid and accurate diagnostic tools. The emergence of the SARS-CoV-2 virus created an urgent demand for accelerated diagnostic methods that could offer both precision and affordability. While RT-PCR tests were widely used for early detection, they were often considered expensive and resource-intensive. This led to the widespread deployment of immunoassay analyzers for detecting antibodies, providing a more cost-effective and efficient alternative. Companies responded swiftly to this demand by launching advanced immunoassay solutions. For instance, Agilent Technologies, Inc. introduced the Agilent Dako SARS-CoV-2 enzyme-linked immunoassay kit, designed to detect SARS-CoV-2 antibodies in human serum or plasma. The pandemic heightened awareness about the capabilities of immunoassay analyzers, accelerating technological developments and market expansion.

The increasing prevalence of chronic diseases has driven continuous advancements in immunoassay technologies. The emergence of new infectious diseases, growing concerns over antibiotic resistance, and the rising demand for personalized medicine have spurred the need for highly sensitive, specific, and rapid immunoassay tests. Various companies are investing in innovative solutions to meet these evolving healthcare needs. Diamond Diagnostics, for example, is committed to enhancing immunoassay diagnostics by manufacturing high-quality, cost-effective consumables and accessories for immunoassay analyzers. Such innovations contribute to the expansion of the market, ensuring that healthcare providers have access to reliable and advanced diagnostic tools.

In addition to technological advancements, strategic collaborations among key industry players are significantly contributing to market growth. Companies are increasingly forming partnerships to strengthen their immunoassay capabilities, support therapeutic advancements, and facilitate clinical adoption. A notable example is the collaboration between Beckman Coulter, Inc. and Fujirebio in July 2023. This partnership aims to enhance immunoassay applications in neurodegenerative disease research, clinical trials, routine diagnostics, and reimbursement processes. By combining expertise and resources, these collaborations are driving innovation and improving the accessibility of advanced diagnostic solutions.

Global Immunoassay Analyzers Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For the purpose of this study, Grand View Research has segmented the global Immunoassay analyzers market report on the basis of product, application, end use, region:

Product Outlook (Revenue, USD Million, 2018 - 2030)
Chemiluminescence Immunoassays (CLIA)
Fluorescence Immunoassays (FIA)
Radioimmunoassay
Enzyme-Linked Immunoassay
Consumables and Accessories
Application Outlook (Revenue, USD Million, 2018 - 2030)
Therapeutic Drug Monitoring
Oncology
Cardiology
Endocrinology
Infectious Disease Testing
Autoimmune Disease
Others
End-use Outlook (Revenue, USD Million, 2018 - 2030)
Hospitals & Clinics
Diagnostic Laboratories
Research Institutes
Regional Outlook (Revenue in USD Million, 2018 - 2030)
North America
- U.S.
- Canada
- Mexico
Europe
- UK
- Germany
- France
- Italy
- Spain
- Sweden
- Denmark
- Norway
Asia Pacific
- Japan
- China
- India
- Australia
- South Korea
- Thailand
Latin America
- Brazil
- Argentina
Middle East and Africa
- Saudi Arabia
- South Africa
- UAE
- Kuwait

Chapter 1. Methodology and Scope

1.1. Market Segmentation & Scope
1.2. Segment Definitions
- 1.2.1. Product
- 1.2.2. Application
- 1.2.3. End Use
- 1.2.4. Regional scope
- 1.2.5. Estimates and forecasts timeline.
1.3. Research Methodology
1.4. Information Procurement
- 1.4.1. Purchased database
- 1.4.2. GVR's internal database
- 1.4.3. Secondary sources
- 1.4.4. Primary research
- 1.4.5. Details of primary research
1.5. Information or Data Analysis
- 1.5.1. Data analysis models
1.6. Market Formulation & Validation
1.7. Model Details
- 1.7.1. Commodity flow analysis (Model 1)
- 1.7.2. Approach 1: Commodity flow approach
- 1.7.3. Volume price analysis (Model 2)
- 1.7.4. Approach 2: Volume price analysis
1.8. List of Secondary Sources
1.9. List of Primary Sources
1.10. Objectives

Chapter 2. Executive Summary

2.1. Market Outlook
2.2. Segment Outlook
- 2.2.1. Product outlook
- 2.2.2. Application outlook
- 2.2.3. End Use outlook
- 2.2.4. Regional outlook
2.3. Competitive Insights

Chapter 3. Immunoassay Analyzers Market Variables, Trends & Scope

3.1. Market Lineage Outlook
- 3.1.1. Parent market outlook
- 3.1.2. Related/ancillary market outlook.
3.2. Market Dynamics
- 3.2.1. Market driver analysis
  - 3.2.1.1. Rising Prevalence of chronic and infectious diseases
  - 3.2.1.2. Technological advancements
  - 3.2.1.3. Growing adoption of personalized products
  - 3.2.1.4. Growing investments and collaborations
- 3.2.2. Market restraint analysis
  - 3.2.2.1. High costs and operational complexity
3.3. Immunoassay Analyzers Market Analysis Tools
- 3.3.1. Industry Analysis - Porter's
- 3.3.2. PESTEL Analysis
3.4. Case Study

Chapter 4. Immunoassay Analyzers Market: Product Estimates & Trend Analysis

4.1. Products Market Share, 2024 & 2030
4.2. Segment Dashboard
4.3. Immunoassay Analyzers Market: Product Movement Analysis
4.4. Immunoassay Analyzers Market Size & Trend Analysis, by Product, 2018 to 2030 (USD Million)
4.5. Chemiluminescence Immunoassays (CLIA)
- 4.5.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.6. Fluorescence Immunoassays (FIA)
- 4.6.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.7. Radioimmunoassay
- 4.7.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.8. Enzyme-Linked Immunoassay
- 4.8.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.9. vConsumables and Accessories
- 4.9.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.10. Consumables and Accessories
- 4.10.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Immunoassay Analyzers Market: Application Estimates & Trend Analysis

5.1. Application Market Share, 2024 & 2030
5.2. Segment Dashboard
5.3. Global Immunoassay Analyzers Market by Application Outlook
5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
5.5. Therapeutic Drug Monitoring
- 5.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
5.6. Oncology
- 5.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
5.7. Cardiology
- 5.7.1. Market estimates and forecasts 2018 to 2030 (USD Million)
5.8. Endocrinology
- 5.8.1. Market estimates and forecasts 2018 to 2030 (USD Million)
5.9. Infectious Disease Testing
- 5.9.1. Market estimates and forecasts 2018 to 2030 (USD Million)
5.10. Autoimmune Disease
- 5.10.1. Market estimates and forecasts 2018 to 2030 (USD Million)
5.11. Others
- 5.11.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Immunoassay Analyzers Market: End Use Estimates & Trend Analysis

6.1. End Use Market Share, 2024 & 2030
6.2. Segment Dashboard
6.3. Global Immunoassay Analyzers Market by End Use Outlook
6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
6.5. Hospitals & Clinics
- 6.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
6.6. Diagnostic Laboratories
- 6.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
6.7. Research Institutes
- 6.7.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Immunoassay Analyzers Market: Regional Estimates & Trend Analysis

7.1. Regional Market Share Analysis, 2024 & 2030
7.2. Regional Market Dashboard
7.3. Global Regional Market Snapshot
7.4. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
7.5. North America
- 7.5.1. North America: SWOT Analysis
- 7.5.2. U.S.
  - 7.5.2.1. Key country dynamics
  - 7.5.2.2. Regulatory framework/Reimbursement
  - 7.5.2.3. Competitive scenario
  - 7.5.2.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
- 7.5.3. Canada
  - 7.5.3.1. Key country dynamics
  - 7.5.3.2. Regulatory framework/Reimbursement
  - 7.5.3.3. Competitive scenario
  - 7.5.3.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
- 7.5.4. Mexico
  - 7.5.4.1. Key country dynamics
  - 7.5.4.2. Regulatory framework/Reimbursement
  - 7.5.4.3. Competitive scenario
  - 7.5.4.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
7.6. Europe
- 7.6.1. Europe: SWOT Analysis
- 7.6.2. UK
  - 7.6.2.1. Key country dynamics
  - 7.6.2.2. Regulatory framework/Reimbursement
  - 7.6.2.3. Competitive scenario
  - 7.6.2.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
- 7.6.3. Germany
  - 7.6.3.1. Key country dynamics
  - 7.6.3.2. Regulatory framework/Reimbursement
  - 7.6.3.3. Competitive scenario
  - 7.6.3.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
- 7.6.4. France
  - 7.6.4.1. Key country dynamics
  - 7.6.4.2. Regulatory framework/Reimbursement
  - 7.6.4.3. Competitive scenario
  - 7.6.4.4. France market estimates and forecasts 2018 to 2030 (USD Million)
- 7.6.5. Italy
  - 7.6.5.1. Key country dynamics
  - 7.6.5.2. Regulatory framework/Reimbursement
  - 7.6.5.3. Competitive scenario
  - 7.6.5.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
- 7.6.6. Spain
  - 7.6.6.1. Key country dynamics
  - 7.6.6.2. Regulatory framework/Reimbursement
  - 7.6.6.3. Competitive scenario
  - 7.6.6.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
- 7.6.7. Norway
  - 7.6.7.1. Key country dynamics
  - 7.6.7.2. Regulatory framework/Reimbursement
  - 7.6.7.3. Competitive scenario
  - 7.6.7.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
- 7.6.8. Sweden
  - 7.6.8.1. Key country dynamics
  - 7.6.8.2. Regulatory framework/Reimbursement
  - 7.6.8.3. Competitive scenario
  - 7.6.8.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
- 7.6.9. Denmark
  - 7.6.9.1. Key country dynamics
  - 7.6.9.2. Regulatory framework/Reimbursement
  - 7.6.9.3. Competitive scenario
  - 7.6.9.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
7.7. Asia Pacific
- 7.7.1. Asia Pacific: SWOT Analysis
- 7.7.2. Japan
  - 7.7.2.1. Key country dynamics
  - 7.7.2.2. Regulatory framework/Reimbursement
  - 7.7.2.3. Competitive scenario
  - 7.7.2.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
- 7.7.3. China
  - 7.7.3.1. Key country dynamics
  - 7.7.3.2. Regulatory framework/Reimbursement
  - 7.7.3.3. Competitive scenario
  - 7.7.3.4. China market estimates and forecasts 2018 to 2030 (USD Million)
- 7.7.4. India
  - 7.7.4.1. Key country dynamics
  - 7.7.4.2. Regulatory framework/Reimbursement
  - 7.7.4.3. Competitive scenario
  - 7.7.4.4. India market estimates and forecasts 2018 to 2030 (USD Million)
- 7.7.5. Australia
  - 7.7.5.1. Key country dynamics
  - 7.7.5.2. Regulatory framework/Reimbursement
  - 7.7.5.3. Competitive scenario
  - 7.7.5.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
- 7.7.6. South Korea
  - 7.7.6.1. Key country dynamics
  - 7.7.6.2. Regulatory framework/Reimbursement
  - 7.7.6.3. Competitive scenario
  - 7.7.6.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
- 7.7.7. Thailand
  - 7.7.7.1. Key country dynamics
  - 7.7.7.2. Regulatory framework/Reimbursement
  - 7.7.7.3. Competitive scenario
  - 7.7.7.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
7.8. Latin America
- 7.8.1. Latin America: SWOT Analysis
- 7.8.2. Brazil
  - 7.8.2.1. Key country dynamics
  - 7.8.2.2. Regulatory framework/Reimbursement
  - 7.8.2.3. Competitive scenario
  - 7.8.2.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
- 7.8.3. Argentina
  - 7.8.3.1. Key country dynamics
  - 7.8.3.2. Regulatory framework/Reimbursement
  - 7.8.3.3. Competitive scenario
  - 7.8.3.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
7.9. MEA
- 7.9.1. MEA: SWOT Analysis
- 7.9.2. South Africa
  - 7.9.2.1. Key country dynamics
  - 7.9.2.2. Regulatory framework/Reimbursement
  - 7.9.2.3. Competitive scenario
  - 7.9.2.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
- 7.9.3. Saudi Arabia
  - 7.9.3.1. Key country dynamics
  - 7.9.3.2. Regulatory framework/Reimbursement
  - 7.9.3.3. Competitive scenario
  - 7.9.3.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
- 7.9.4. UAE
  - 7.9.4.1. Key country dynamics
  - 7.9.4.2. Regulatory framework/Reimbursement
  - 7.9.4.3. Competitive scenario
  - 7.9.4.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
- 7.9.5. Kuwait
  - 7.9.5.1. Key country dynamics
  - 7.9.5.2. Regulatory framework
  - 7.9.5.3. Competitive scenario
  - 7.9.5.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. Competitive Landscape

8.1. Recent Developments & Impact Analysis, By Key Market Participants
8.2. Company/Competition Categorization
8.3. Vendor Landscape
- 8.3.1. List of key distributors and channel partners
- 8.3.2. Key customers
- 8.3.3. Key company market share analysis, 2024
- 8.3.4. Siemens Healthineers AG
  - 8.3.4.1. Company overview
  - 8.3.4.2. Financial performance
  - 8.3.4.3. Services benchmarking
  - 8.3.4.4. Strategic initiatives
- 8.3.5. BIOMERIEUX
  - 8.3.5.1. Company overview
  - 8.3.5.2. Financial performance
  - 8.3.5.3. Services benchmarking
  - 8.3.5.4. Strategic initiatives
- 8.3.6. FAbbott
  - 8.3.6.1. Company overview
  - 8.3.6.2. Financial performance
  - 8.3.6.3. Services benchmarking
  - 8.3.6.4. Strategic initiatives
- 8.3.7. QuidelOrtho Corporation
  - 8.3.7.1. Company overview
  - 8.3.7.2. Financial performance
  - 8.3.7.3. Services benchmarking
  - 8.3.7.4. Strategic initiatives
- 8.3.8. Sysmex Corporation
  - 8.3.8.1. Company overview
  - 8.3.8.2. Financial performance
  - 8.3.8.3. Services benchmarking
  - 8.3.8.4. Strategic initiatives
- 8.3.9. BD
  - 8.3.9.1. Company overview
  - 8.3.9.2. Financial performance
  - 8.3.9.3. Services benchmarking
  - 8.3.9.4. Strategic initiatives
- 8.3.10. Thermo Fisher Scientific Inc.
  - 8.3.10.1. Company overview
  - 8.3.10.2. Financial performance
  - 8.3.10.3. Services benchmarking
  - 8.3.10.4. Strategic initiatives
- 8.3.11. F. Hoffmann-La Roche Ltd
  - 8.3.11.1. Company overview
  - 8.3.11.2. Financial performance
  - 8.3.11.3. Services benchmarking
  - 8.3.11.4. Strategic initiatives
- 8.3.12. Beckman Coulter, Inc.
  - 8.3.12.1. Company overview
  - 8.3.12.2. Financial performance
  - 8.3.12.3. Services benchmarking
  - 8.3.12.4. Strategic initiatives
- 8.3.13. DiaSorin S.p.A.
  - 8.3.13.1. Company overview
  - 8.3.13.2. Financial performance
  - 8.3.13.3. Services benchmarking
  - 8.3.13.4. Strategic initiatives

한글목차

면역 측정 분석기 시장 동향 :

목차

제1장 조사 방법과 범위

제2장 주요 요약

제3장 면역측정 분석기 시장 변수, 동향, 범위

제4장 면역측정 분석기 시장 : 제품 추정·동향 분석

제5장 면역측정 분석기 시장 : 용도 추정·동향 분석

제6장 면역측정 분석기 시장 : 최종 용도 추정·동향 분석

제7장 면역측정 분석기 시장 : 지역 추정·동향 분석